New upcoming treatments for Cushing’s syndrome promise to improve patient’s quality of life, a new report by pharmaceutical intelligence expert GlobalData has found.
The new report* found that Cushing’s syndrome patients can expect increasingly safe and effective pharmaceutical treatment options in the future, due to the expected launch of three late-stage pipeline molecules.
Cushing's syndrome is most commonly caused by a tumor in the pituitary gland, which produces large amounts of cortisol hormones. Current treatment options available for Cushing’s syndrome consist of surgery, radiation therapy and drug therapy, or a combination of these treatments.
No Food and Drug Administration (FDA) approved drugs currently exist to treat Cushing’s syndrome, leading the therapeutics market to be dominated by off-label drugs. Drug therapy is not generally considered the first line of treatment for the condition, but is primarily prescribed in cases of relapse or for patients who are unsuitable for surgery.
Steroidogenesis inhibitors are commonly used in drug therapy for Cushings syndrome, but are associated with serious adverse effects including excessive sedation, gynecomastia (male breast development), hirsutism (excessive hairiness) and severe hepatotoxicity (liver damage). These side effects represent a major concern for prescribing physicians, and the patients themselves. In addition, no drug is currently available that can alter the size of the tumor, as off-label drugs only provide symptomatic relief and reduce cortisol hormone levels.
However, GlobalData’s analysis shows that the therapeutics pipeline is strong, with eight molecules in various phases of development, including three late stage First-In-Class (FIC) pipeline molecules named Korlym (mifepristone), pasireotide (SOM230) and Mifedren (mifepristone), which are expected to launch in the near future. These drugs offer impressive safety and efficacy profiles, which promise to increase patient compliance and quality of life.
GlobalData estimates that the global Cushing’s syndrome therapeutics market was worth $45.2m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 6.2% during 2006–2011. This may have been due to an increased diagnosis rate of Cushing’s syndrome as a result of growing awareness among patients and physicians. The market is expected to witness a CAGR of 9.1% throughout 2011-2019 to reach a value of $90.8m by 2019, due to the expected launch of late-stage pipeline molecules.
NOTES TO EDITORS
*Cushing's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
The report is an essential source of insight into global Cushing’s syndrome therapeutics, providing actionable analysis on the key trends affecting the market, including pipeline products. The report also provides insights into the prevalent competitive landscape and key players expected to significantly alter the market positioning of the current market leaders. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant,reliable and actionable strategic business intelligence available for a wide range of industries
For further details, please Contact Us.